|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM356183157 |
| 003 |
DE-627 |
| 005 |
20231227131229.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202300934
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1225.xml
|
| 035 |
|
|
|a (DE-627)NLM356183157
|
| 035 |
|
|
|a (NLM)37114740
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Park, Jun-Young
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Pancreatic Tumor-Targeting Stemsome Therapeutics
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.07.2023
|
| 500 |
|
|
|a Date Revised 13.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Owing to the intrinsic ability of stem cells to target the tumor environment, stem-cell-membrane-functionalized nanocarriers can target and load active anticancer drugs. In this work, a strategy that focuses on stem cells that self-target pancreatic cancer cells is developed. In particular, malignant deep tumors such as pancreatic cancer cells, one of the intractable tumors that currently have no successful clinical strategy, are available for targeting and destruction. By gaining the targeting ability of stem cells against pancreatic tumor cells, stem cell membranes can encapsulate nano-polylactide-co-glycolide loaded with doxorubicin to target and reduce deep pancreatic tumor tissues. Considering the lack of known target proteins on pancreatic tumor cells, the suggested platform technology can be utilized for targeting any malignant tumors in which surface target receptors are unavailable
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PLGA nanoparticles
|
| 650 |
|
4 |
|a ectosomes
|
| 650 |
|
4 |
|a pancreatic cancer
|
| 650 |
|
4 |
|a stem cells
|
| 650 |
|
4 |
|a surface target receptors
|
| 650 |
|
4 |
|a tumor targeting
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 700 |
1 |
|
|a Park, Jun Young
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jeong, Yong-Gyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Joo-Hwan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Yeon Ho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Sang-Hyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Khang, Dongwoo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 30 vom: 13. Juli, Seite e2300934
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:30
|g day:13
|g month:07
|g pages:e2300934
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202300934
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 30
|b 13
|c 07
|h e2300934
|